Skip Navigation
 

Department of Microbiology and Immunology

Steve Tomlinson

Steve Tomlinson, Ph.D.Tomlinson Picture

Professor and Vice Chair for Research & Faculty Development
Microbiology & Immunology

1990-1991       Postdoctoral Fellow, Dept. of Molecular Biology,
                           University of Florida at Gainesville

Education
1989                 Ph.D., University of Cambridge, UK

Contact Info
tomlinss@musc.edu
Tel: 843-792-1450
CRI 213

Research Interests

Research activities are focused on the biology of the complement system. Complement is a group of over 30 soluble and cell surface proteins that represent a crucial component of immune system. The laboratory is involved in the following areas of study

1. INFLAMMATION AND ALLOIMMUNITY: We are investigating the role of complement in inflammation and mechanisms of injury in various disease conditions, including hepatic and cardiac ischemia reperfusion injury, stroke and spinal cord injury. We are also working in the field or organ transplantation with a focus on complement-dependent inflammatory mechanisms, and how inflammation can shape an alloimmune response. A concurrent interest in the laboratory is the development of complement therapeutics, in particular complement inhibitors that can be targeted to sites of injury and disease.

2. CANCER: Complement plays an important role in both the induction and effector phases of an immune response to cancer. Immunity may be naturally induced or may be the result of passive or active immunotherapies. We are studying the role of complement in tumor immunity and investigating strategies to enhance a normally ineffective immune response to tumor cells. To this end, we are investigating mechanisms by which complement activation products and inflammation modulate both humoral and T cell responses to tumors.

Publications (selected from 110) | Additional Publications

He S, Atkinson C, Qiao F, Cianflone K, Chen X, and Tomlinson S. (2009) A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration, and clinical implications. J. Clin. Invest. 119:2304-16.

He S, Atkinson C, Evans Z, Elliot J, Southwood M, Elvington A, Chavin K, Tomlinson, S. (2009) A role for complement in the susceptibility of steatotic livers to ischemia and reperfusion injury. J. Immunol. 183: 4764-4772.

Atkinson C, Mosely E, Varela JC, Stoica S, Large S, Goddard M, and Tomlinson S. (2009) Complement dependent inflammation and Injury in a murine model of brain dead donor hearts. Circ. Res. 105:1094-1101. PMCID: PMC2783176

Hylton DJ, Hoffman SM, Van Roojen N, Tomlinson S, and Fleming SD. (2010) Macrophage produced IL-12p70 mediates hemorrhage-induced damage in a complement dependent manner. Shock. 35:134-40.

Qiao F, Atkinson C, Kindy MS, Shunmugavel A, Morgan BP, and Tomlinson S. (2010) The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. Am. J. Pathol., 177:3061-70. PMC299326

Atkinson C, He S, Morris K, Qiao F, Casey S, Goddard M, and Tomlinson S. ((2010) Targeted complement inhibitors protect against post-transplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J. Immunol. 185:7007-7013. PMID: 20962256

Sekine H, Kinser TTH, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson G, and Tomlinson S. (2011) The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum. 63:1076-1085.

Zhang Z, Knoepp SM, Ku H, Sansbury M, Xie Y, Chahal MS, Tomlinson S, and Meier KE. (2011) Differential expression of FAK anf Pyk2 in metastatic and non-metastatic EL4 lymphoma cell lines. Clin. Exp. Metastasis. 28:551-65.

Sekine H, Ruiz P, Gilkeson GS, and Tomlinson S. (2011) The dual role of complement in the progression of renal disease in NZB/W F1 mice and alternative pathway inhibition. Mol. Immunol. 49: 317-323.

Sun S, Wang H, An Y, Zhao G, Guo Y, Song H, Kou Z, Qiao F, Atkinson C, Jiang S, Tomlinson S, Zhou Y. (2011) Complement Inhibition alleviates paraquat-induced acute lung injury. Am. J. Resp. Cell Mol. Biol. 45:834-42.

Khan MA, Jiang X, Beilke J, Holers VM, Atkinson C, Tomlinson S, and Nicolls, M. (2011) CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ. Research. 109:1290-301.

Ramos TN, Darley MM, Weckbach S, Stahel PF, Tomlinson S, and Barnum SR. (2012) The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria. J. Biol. Chem. 287:24734-8.

Elvington A, Atkinson C, Kulik L, Zhu H, Yu J, Kindy MS, Holers VM, and Tomlinson S. (2012) Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J. Immunol. 188:14660-8.

Schepp-Berglind J, Atkinson C, Elvington M, Qiao F, Mannon P, and Tomlinson S. (2012) Complement-dependent injury and protection in a murine model of acute DSS-induced colitis. J. Immunol. 188:6309-18.

Elvington M, Huang Y, Morgan BP, Qiao F, van Rooijen N, Atkinson C, and Tomlinson S. (2012) A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood, 119:6043-51.

Research Support

Title: Complement, anti-tumor immunity and apoptosis-based therapy
Agency: NIH/NCI
Role: PI
Funding Period: 1/1/12-12/31/17

Title: The complement system and spinal cord injury
Agency: Dept. Veteran’s Affairs
Role: PI
Funding Period: 11/15/11-11/14/15

Title: Role of complement in brain death induced injury to donor hearts
Agency: NIH/NHLB
Role: PI
Funding Period: 8/1/07-7/31/12

Title: Role of complement in inflammatory bowel disease
Agency: Crohn’s and Colitis Foundation of America
Role: PI
Funding Period: 1/7/10-06/30/13

Title: Complement and cognitive recovery after stroke
Agency: Alexion Pharmaceuticals
Role: PI
Funding Period: 9/1/12-8/31/14

Title: The role of complement in the pathogenesis of emphysema
Agency: NIH/NHLB
Role: Co-I
Funding Period: 3/1/10-2/28/15

Title: Alternative Pathway of Complement Activation in Age-Related Macular Degeneration
Agency: NIH/NEI
Role: Co-I
Funding Period: 7/01/10-6/30/15

Title: Therapeutic intervention in traumatic brain injury
Agency: Dept. Veteran’s Affairs
Role: Co-I
Funding Period: 6/1/10-5/31/13

top of page

 
 
 

© 2012  Medical University of South Carolina | Disclaimer